Clinical blood transfusion and blood transfusion-related immunity are critical to the survival of the transplant. With the improvement of transplantation technology, liver transplantation, kidney transplantation, small intestine transplantation,lung transplantation uterus transplantation, hematopoietic stem cell transplantation have been realized, and xenogeneic organ transplantation is also actively exploring. Researchers have gradually gained a new understanding of transplantation-related blood transfusion. This paper expatiated on blood immunology related to organ transplantation and hematopoietic stem cell transplantation, perioperative blood transfusion during transplantation and xenotransplantation in the future, in order to provide new ideas for blood transfusion in transplantation technology.

Objective To investigate the effect of Lymphoplasmapheresis (LPE) on patients of ABO-incompatible living donor kidney transplantation (ABOi-KT). Methods Eight ABOi-KT patients received LPE treatment 57 times before surgery. Blood cell count and plasma protein content were compared before and after LPE treatment. Perioperative blood group antibody titers were monitored. The occurrence of adverse reactions was analyzed. Results There were no significant differences in white blood cell count, neutrophil count, hemoglobin and red blood cell count between before and after LPE treatment (P>0.05). Lymphocyte count and platelet count decreased after treatment (P<0.05). There were no significant changes in plasma total protein and albumin between before and after treatment (P<0.05). The amount of globulin decreased after treatment (P<0.05). Each patient received several LPE treatments to ensure that the blood group antibody titers on the day of ABOi-KT surgery was less than 1∶16, and there was no titer rebound in two weeks after surgery. The incidence of adverse reactions in patients received LPE treatment was 8.8%. Conclusion Preoperative LPE treatment for ABOi-KT patients is helpful for safe and effective operation.